Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 1

NCT04429087

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours T…

This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study…

United States, Germany300 participantsStarted 2020-07-29

Treatment: Obrixtamig - parenteral 1, Obrixtamig - parenteral 2

RecruitingPhase 1/2

NCT07278479

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol…

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Sma…

United States138 participantsStarted 2026-04

Treatment: [212Pb]Pb-MP0712, [203Pb]Pb-MP0712

All recent trials (3 shown)

Active — Not RecruitingPhase 1

NCT05879978

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by Peop…

This study is open to adults with small cell lung cancer and other neuroendocrine tumours that are positive for the tumour marker Delta-like 3 (DLL3). The study…

Belgium, France45 participantsStarted 2023-06-27

Treatment: Obrixtamig, Ezabenlimab